Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 6, 2013, Pages 458-463

  Feng, Dapeng ^a   Yang, Xinghai ^a   Li, Shufeng ^b   Liu, Tielong ^a   Wu, Zhipeng ^a   Song, Yuanlin ^c   Wang, Jian ^d   Gao, Wenwu ^e   Huang, Quan ^a   Huang, Wending ^a   Zheng, Wei ^a   Xiao, Jianru ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG PEANUT RESEARCH INSTITUTE   (China)

^d Shanghai Corps Hospital   (China)

^e SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; EWING SARCOMA; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD;

ADOLESCENT; ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SARCOMA, EWING;

EID: 84878528410     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0488     Document Type: Article

References (21)

1. Buonavista N, Balzano C, Pontarotti P, et al. (1992) Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics 13:856-861.
2. Chikuma S, Imboden JB, Bluestone JA (2003) Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 197:129-135. (Pubitemid 36110264)
3. Contardi E, Palmisano GL, Tazzari PL, et al. (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apo-ptosis upon ligand interaction. Int J Cancer 117:538-550. (Pubitemid 41504541)
4. Dorfman HD, Czerniak B (1995) Bone cancers. Cancer. 75(1 Suppl):203-210.
5. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618. (Pubitemid 34752469)
6. Erfani N, Razmkhah M, Talei AR, et al. (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165:114-120. (Pubitemid 43343504)
7. Ghaderi A, Yeganeh F, Kalantari T, et al. (2004) Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86:1-7. (Pubitemid 38918893)
8. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366-373. (Pubitemid 34173328)
9. Hadinia A, Hossieni SV, Erfani N, et al. (2007) CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22:2283-2287. (Pubitemid 350145629)
10. Hodi FS, Mihm MC, Soiffer RJ, et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717. (Pubitemid 36457795)
11. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736. (Pubitemid 26102823)
12. Ligers A, Teleshova N, Masterman T, et al. (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2:145-152. (Pubitemid 33674879)
13. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191-212. (Pubitemid 23115006)
14. Liu Y, He Z, Feng D, et al. (2011) Cytotoxic T-lymphocyte anti-gen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol 30:1051-1055.
15. Masteller EL, Chuang E, Mullen AC, et al. (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319-5327. (Pubitemid 30305211)
16. Phan GQ, Yang JC, Sherry RM, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377. (Pubitemid 36842552)
17. Pure E, Allison JP, Schreiber RD (2005) Breaking down the barriers to cancer immunotherapy. Nat Immunol 6:1207-1210. (Pubitemid 43045629)
18. Sun T, Zhou Y, Yang M, et al. (2008) Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68:7025-7034.
19. Ueda H, Howson JM, Esposito L, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511. (Pubitemid 36648570)
20. Wang J, Zhou Y, Feng D, et al. (2012) CD86 +1057G/A polymorphism and susceptibility to Ewing's sarcoma: a case-control study. DNA Cell Biol 31:537-540.
21. Wang W, Wang J, Song H, et al. (2011) Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers 15: 503-506.